Drug Target (Synonym) | Effect on T-cells and immune system | Compound (Synonym) | Compound (Trade name) | Drug type (application) | Status | Indication |
---|---|---|---|---|---|---|
CD80 (B7-1) CD86 (B7-2) | T-cell costimulation blocker, inhibits T-cell proliferation and production of cytokines | Belatacept (LEA29Y) | BMS (Nulojix) | CTLA4 fusion-Ig, costimulation blocker | FDA approval 15.11.2011 EMA approval 07.07.2011 | Prophylaxis of renal graft rejection Prophylaxis of renal graft rejection |
Abatacept | BMS (Orencia) | CTLA4 fusion-Ig, costimulation blocker | FDA approval 31.07.2011 EMA approval 25.01.2010 | Rhematoid arthritis; Polyarticular juvenile idiopathic arthritis | ||
CD80 | Activates ADCC on B-NHL cells with upregulated CD80 | Galiximab (IDEC-114) | Biogen | Humanized MAb IgG1, (i.v.) | Phase I/II Phase II | Untreated follicular lymphoma Relapsed/refractory M. Hodgkin |
CD80 DNMT1 | Upregulation of CD80 on cancer cells - > costimulatory activation of T-cells | Decitabine | Janssen-Cilag (Dacogen) | Deoxycytidine analogue, i.v. (D1-5, Q6W) | FDA approval 02.05.2006 EMA approval 28.09.2012 | Myelodysplastic syndromes Acute myeloid leukemia |
CD86 HDAC | Upregulation of CD86 on cancer cells, HDAC-I - > costimulatory activation of T-cells | Romidepsin (FR901228) | Gloucester Pharmaceuticals, Celgene (Istodax) | Depsipeptide, (i.v. Q1W) | FDA approval 05.11.2009 EMA refused approval 09.07.2012 | Cutaneous T-NHL, PTCL |
CD137-L | Induction of differentiation of AML cell samples in vitro | - | - | Recombinant CD137-L protein | Preclinical | In vitro |
CD252 (OX40-L) | Binds and activates Ox40 by mimicking Ox40-L - > proliferation of TAA specific T-effector cells - > activation of anti-tumor immune response | MEDI-6383 | MedImmune | Fusion protein | Phase I | Advanced solid tumors |
CD252 (OX40-L) | Binds and inhibits Ox40L and the interaction with Ox40 - > inhibition of allergen induced immune response | Oxelumab (huMAb OX40L) (R4930) | Genentech | Human MAb IgG1, (i.v.) | Phase II | Mild allergic asthma |
CD276 (B7-H3) | Inhibits CD276 | Enoblituzumab (MGA-271) | MacroGenics | Humanized MAb IgG1ĸ, (i.v.) | Phase I | B7-H3 expressing refractory solid tumors |
CD276 (B7-H3) CD3 | Redirection of T-cells to kill B7-H3 overexpressing tumor cells | MGD-009 | MacroGenics | Dual affinity retargeting protein | Phase I | B7-H3 expressing unresectable or metastatic solid tumors |